SYNTHROID 137 MCG
LEVOTHYROXINE SODIUM : 137 MCG · DIN 02233852 · BGP PHARMA ULC
Health Canada status: MARKETED
What is SYNTHROID?
SYNTHROID 137 MCG contains LEVOTHYROXINE SODIUM : 137 MCG. It is listed in the Health Canada Drug Product Database under DIN 02233852, held by BGP PHARMA ULC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 10-Mar-2016. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is SYNTHROID used for?
Replacement/supplemental therapy for hypothyroidism (primary, secondary, tertiary); pituitary TSH suppression for well-differentiated papillary or follicular thyroid carcinoma.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02233852 |
|---|---|
| Brand name | SYNTHROID |
| Generic / active ingredient | LEVOTHYROXINE SODIUM : 137 MCG |
| Manufacturer | BGP PHARMA ULC |
| Strength | 137 MCG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | H03AA01 LEVOTHYROXINE SODIUM |
| AHFS class | 84:80.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 10-Mar-2016 |
| Original market date | 1998-05-04 00:00:00 |
How is it administered?
Administer once daily on empty stomach, 0.5-1 hour before breakfast. Individualize dose based on TSH/T4 levels. Usual adult dose ~1.7 mcg/kg/day. Titrate in 12.5-25 mcg increments.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in the provided text sections (refer to section 11 in full monograph).
How is it supplied?
Bottles of 90 and 1000 tablets (300 mcg strength available in bottles of 90 only).
Contraindications
Hypersensitivity; untreated subclinical or overt thyrotoxicosis; acute MI, myocarditis, or pancarditis; uncorrected adrenal insufficiency; pregnant women treated with anti-thyroid drugs.
Warnings and precautions
Not for obesity/weight loss (Serious Warning). Narrow therapeutic index. Exercise caution in patients with cardiovascular disorders. Monitor for iatrogenic hyperthyroidism.
Is LEVOTHYROXINE SODIUM in shortage in Canada?
A Canadian shortage report is on file for this molecule: Resolved — reported by FRESENIUS KABI CANADA LTD, last seen 24 Apr 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code H03AA01 LEVOTHYROXINE SODIUM. 33 of 109 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-LEVOTHYROXINE | 100 MCG | TABLET | APOTEX INC | MARKETED | DIN 02534681 |
| APO-LEVOTHYROXINE | 112 MCG | TABLET | APOTEX INC | MARKETED | DIN 02550741 |
| APO-LEVOTHYROXINE | 125 MCG | TABLET | APOTEX INC | MARKETED | DIN 02550768 |
| APO-LEVOTHYROXINE | 137 MCG | TABLET | APOTEX INC | MARKETED | DIN 02550776 |
| APO-LEVOTHYROXINE | 150 MCG | TABLET | APOTEX INC | MARKETED | DIN 02550784 |
| APO-LEVOTHYROXINE | 175 MCG | TABLET | APOTEX INC | MARKETED | DIN 02550792 |
| APO-LEVOTHYROXINE | 200 MCG | TABLET | APOTEX INC | MARKETED | DIN 02550806 |
| APO-LEVOTHYROXINE | 25 MCG | TABLET | APOTEX INC | MARKETED | DIN 02550709 |
| APO-LEVOTHYROXINE | 300 MCG | TABLET | APOTEX INC | MARKETED | DIN 02534703 |
| APO-LEVOTHYROXINE | 50 MCG | TABLET | APOTEX INC | MARKETED | DIN 02550717 |
Who else supplies LEVOTHYROXINE SODIUM worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. LEVOTHYROXINE SODIUM appears in 432 registered pack listings across 11 markets, published on 8 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.